Until 2017, no U.S. state had a law specifically addressing non-FDA-approved stem cell therapy at the provider level. Since California broke that ground, the count has grown to at least half a dozen states with disclosure or authorization frameworks, and the pace is accelerating: Florida, Utah, and Wyoming all enacted or expanded frameworks across 2025 and 2026, with Wyoming’s law taking effect July 1, 2026. What follows is a reference map for physicians placing their own state, and their patients’ states, on that landscape as of June 2026.
TLDR: As of June 2026, at least six states have stem cell laws at the provider level. They split into two kinds: authorization laws (Florida, Wyoming, and the proposed Arizona bill) that permit physician-performed non-FDA-approved therapy under conditions, and disclosure laws (California, Utah) that only require telling patients the FDA status. Effective dates, posting rules, consent and supply-chain obligations, and penalties vary by state, and several specifics, especially for Nevada and the not-yet-enacted Arizona bill, must be verified against primary sources. Every state law operates under the same federal floor: tissue must qualify as a 361 HCT/P or be used under an active IND. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A physician practicing across state lines, or seeing patients who travel for care, cannot assume one rulebook. The framework that applies follows the encounter, and the frameworks differ in kind, not just in detail. The sections below give the map and, more importantly, the limits of the map.
Why the State Landscape Matters
The legislative activity is not slowing. California’s 2017 disclosure law sat alone for years; now Florida and Utah have authorization or disclosure-plus-supply-chain regimes in force, Wyoming’s authorization law is days from taking effect, and additional states have bills moving. For a provider, the consequence is concrete: the same service that is a disclosure obligation in California is a conditioned authorization in Florida and an unsettled question in Nevada. Mapping that correctly is the difference between a compliant launch and a board complaint.
The Multi-State Reference Table
This table is a due-diligence starting point, not a substitute for reading each statute. Cells that could not be confirmed from a primary source are marked, and they should be treated as open questions for counsel.
| State | Law and citation | Type | Effective | Who is authorized | Posting requirement | Signed consent | Supply-chain duty | Post-thaw viability report | Penalty |
|---|---|---|---|---|---|---|---|---|---|
| Florida | SB 1768, Ch. 2025-185 (ss. 458.3245, 459.0127) | Authorization | Jul 1, 2025 | MD/DO; orthopedics, wound care, pain only | Ad notice sized to largest type in ad | Yes | No (sourcing-contract duties instead) | Yes, before each use | Board of Medicine discipline; felony for abortion-derived material |
| Utah | 58-1-512 (SB 199 2024, SB 275 2025) | Disclosure + supply chain | 2024; amended 2025 | Practitioners in scope (verify) | Yes, 8.5×11, 40-point, posted | Yes | Yes, supplier notice (SB 275) | Not specified | Unprofessional conduct / DOPL |
| Wyoming | SF 48, W.S. 35-4-1101 et seq. | Authorization | Jul 1, 2026 | MD/DO registered with the board; autologous MSCs only | Not a posting regime | Yes | No | Not specified | Board action barred if compliant; registration required |
| California | SB 512, Bus. & Prof. Code 684 | Disclosure-only | 2018 | Licensed practitioners | Yes, 8.5×11, 40-point, posted and at entrance | Yes, written handout | No | No | Up to $1,000/violation, not on first complaint |
| Nevada | 2023 biological/gene therapy law | Authorization-style (verify) | 2023 | Verify against NRS | Verify | Verify | Verify | Verify | Verify with counsel |
| Arizona | SB 1214, “Stem Cell Therapy Act” | Authorization (PROPOSED, not enacted) | Not in effect; pending 2026 | MD within scope (per bill) | Ad disclosure in prominent type (per bill) | Yes (per bill) | Sourcing/quality controls (per bill) | Yes (per bill) | Civil penalties; felony for abortion-derived material (per bill) |
Two flags on that table deserve emphasis. Arizona’s SB 1214 is a 2026 bill that, as of the most recent reporting, advanced out of a Senate committee to the Senate floor; it is not enacted law, and every Arizona cell describes what the bill would do, not what is in force. Nevada’s specifics are unverified for the reasons set out in the dedicated Nevada discussion. Treat both as moving targets.
The Federal Floor Every State Law Operates Under
No state authorization law overrides the FDA. This is the single most important line on the map, and it is invisible in the table because it applies to every row. Any tissue that does not qualify as a 361 HCT/P under 21 CFR Part 1271 is regulated as a 351 biologic and must be used under an active IND. The FDA continues to warn that no stem cell product is approved for the broad set of conditions marketed by some clinics, and federal enforcement is active. A state law that authorizes a therapy does not authorize a federal violation. The distinction that decides which federal track applies, minimal manipulation and homologous use, is the foundation under all of this.
States to Watch
This section is forward-looking context, not legal advice, and it is unconfirmed by design. Legislative tracking suggests additional states have introduced or are weighing similar measures, and Arizona’s SB 1214 is the most advanced of the current crop. Beyond that, a physician’s only reliable source for their own jurisdiction is the state legislature’s own bill-tracking site and qualified counsel. Do not act on a trend report; act on enacted text.
How to Use This Map as a Provider
Treat the table as the first page of a due-diligence file, not the last. Confirm your state’s current law with qualified healthcare counsel before launching any stem cell service. If your state is not on the list, that does not mean the area is unregulated: federal law and your state medical board’s rules still apply, and the absence of a specific statute is not permission. For a multi-state practice, build a state-by-state compliance matrix with counsel and re-verify it on a schedule, because, as Wyoming’s imminent effective date and Arizona’s pending bill show, the map changes faster than most compliance calendars assume. The market forces driving all this activity are covered in the regenerative medicine market for physicians.
Frequently Asked Questions
What is the difference between an authorization law and a disclosure law?
An authorization law (Florida, Wyoming) affirmatively permits physician-performed non-FDA-approved therapy under defined conditions. A disclosure law (California, Utah) does not grant permission; it requires that if a provider offers such therapy, they disclose the FDA status to the patient.
Is Arizona’s law in effect?
No. Arizona SB 1214 is a 2026 bill that has advanced through committee but is not enacted. Everything described for Arizona is proposed, not current law.
Does any state law remove the need to comply with FDA rules?
No. State laws operate under the federal floor. Tissue must qualify as a 361 HCT/P or be used under an active IND regardless of state law.
Key Takeaways
The state map as of June 2026 is real but uneven, and the most useful thing a provider can take from it is the taxonomy: authorization laws and disclosure laws are different instruments, and treating a disclosure state like an authorization state, or vice versa, is the core error. Florida and Wyoming authorize under conditions; California and Utah require disclosure; Nevada sits in an authorization-style category whose details are not cleanly verifiable; and Arizona is a pending bill, not a law. Underneath every one of them is the unchanged federal floor, where the 361-versus-351 classification governs regardless of what a statute permits. The practical move is to use this map to start a conversation with counsel for each state you touch, re-verify it because it is changing quickly, and remember that banking adipose tissue is a preservation decision separate from any therapy, carrying no guarantee of future use.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians mapping a multi-state compliance posture can contact Save My Fat to discuss how tissue preservation fits. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
